Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03375320 · ClinicalTrials.gov registry record · Phase 3
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
A Phase 3 study of Locally Advanced Lung Neuroendocrine Neoplasm and Lung Neuroendocrine Tumor G2, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 3
- Development phase
- 298
- Enrollment target
- 20
- Study locations
NCT03375320 is a Phase 3 study of Locally Advanced Lung Neuroendocrine Neoplasm and Lung Neuroendocrine Tumor G2 that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 298 participants. The trial reports 20 study locations across 4 states.
The verdict
NCT03375320, a Phase 3 study of Locally Advanced Lung Neuroendocrine Neoplasm and Lung Neuroendocrine Tumor G2, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 298 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Cabozantinib is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Magnetic Resonance Imaging
- DRUG Cabozantinib S-malate
- OTHER Placebo Administration
Study Locations (20)
California
- Kaiser Permanente-Deer Valley Medical Center - Antioch
- PCR Oncology - Arroyo Grande
- Sutter Auburn Faith Hospital - Auburn
- Alta Bates Summit Medical Center-Herrick Campus - Berkeley
- Mills-Peninsula Medical Center - Burlingame
- City of Hope Comprehensive Cancer Center - Duarte
- Epic Care-Dublin - Dublin
- Epic Care Partners in Cancer Care - Emeryville
- Kaiser Permanente-Fremont - Fremont
- Palo Alto Medical Foundation-Fremont - Fremont
- Kaiser Permanente-Fresno - Fresno
- Contra Costa Regional Medical Center - Martinez
- Fremont - Rideout Cancer Center - Marysville
- Memorial Medical Center - Modesto
Arizona
- Kingman Regional Medical Center - Kingman
- Mayo Clinic Hospital in Arizona - Phoenix
- Banner University Medical Center - Tucson - Tucson
- University of Arizona Cancer Center-North Campus - Tucson
Alaska
- Katmai Oncology Group - Anchorage
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 298 participants |
| Start Date | 2018-10-26 |
| Est. Completion | 2026-08-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03375320
The ClinicalTrials.gov registry entry for NCT03375320 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 298 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Locally Advanced Lung Neuroendocrine Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT03375320 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Alaska.
Frequently Asked Questions
What is clinical trial NCT03375320 about?
NCT03375320 is a clinical study titled "Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors". This phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Cabozantinib is a chemotherap...
What is the current status of trial NCT03375320?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 298 participants. The study started on 2018-10-26. Estimated completion is 2026-08-19.
What conditions does trial NCT03375320 study?
This clinical trial studies the following conditions: Locally Advanced Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Tumor G2, Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm, Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm.
What interventions are being tested in trial NCT03375320?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Cabozantinib S-malate (DRUG), Placebo Administration (OTHER).
Who is sponsoring clinical trial NCT03375320?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03375320 being conducted?
This trial has 20 study locations across Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced Lung Neuroendocrine Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Locally Advanced Lung Neuroendocrine Neoplasm
All registered trials for this condition
Lung Neuroendocrine Tumor G2
All registered trials for this condition
Alaska
All trials with a study site in Alaska
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.